(Q50062417)

24 February 2018

title

Genetic epidemiology of ovarian cancer and prospects for polygenic risk prediction. (English)

1 reference

24 February 2018

1 reference

4

Paul D P Pharoah

1 reference

24 February 2018

5

Simon A Gayther

1 reference

24 February 2018

author name string

Michelle R Jones

series ordinal

1

1 reference

24 February 2018

Daniella Kamara

series ordinal

2

1 reference

24 February 2018

Beth Y Karlan

series ordinal

3

1 reference

24 February 2018

language of work or name

English

0 references

publication date

17 October 2017

1 reference

24 February 2018

published in

Gynecologic Oncology

1 reference

24 February 2018

volume

147

1 reference

24 February 2018

issue

3

1 reference

24 February 2018

page(s)

705-713

1 reference

24 February 2018

Whole-genome characterization of chemoresistant ovarian cancer.

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.10.001

Integrated genomic analyses of ovarian carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.10.001

Combination of CA125 and RECAF biomarkers for early detection of ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.10.001

A comparison of CA125, HE4, risk ovarian malignancy algorithm (ROMA), and risk malignancy index (RMI) for the classification of ovarian masses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.10.001

Use of CA125 and HE4 serum markers to predict ovarian cancer in elevated-risk women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.10.001

Transvaginal color Doppler imaging in the detection of ovarian cancer in a large study population.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.10.001

Hormonal etiology of epithelial ovarian cancer, with a hypothesis concerning the role of androgens and progesterone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.10.001

Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.10.001

Parity, age at first childbirth, and risk of ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.10.001

Increased ovarian cancer risk associated with menopausal estrogen therapy is reduced by adding a progestin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.10.001

Menopausal hormone therapy and risk of epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.10.001

Hormone replacement therapy and ovarian cancer risk: a meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.10.001

Ovarian cancer risk factors by histologic subtypes in the NIH-AARP Diet and Health Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.10.001

Ovarian cancer and menopausal hormone therapy in the NIH-AARP diet and health study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.10.001

Prediagnostic circulating follicle stimulating hormone concentrations and ovarian cancer risk

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.10.001

Ovarian cancer and hormone replacement therapy in the Million Women Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.10.001

Menopausal hormone replacement therapy and risk of ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.10.001

Menopausal hormone therapy and ovarian cancer risk in the National Institutes of Health-AARP Diet and Health Study Cohort

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.10.001

Menopausal hormone therapy and risk of ovarian cancer in the European prospective investigation into cancer and nutrition

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.10.001

Tubal ligation and risk of ovarian cancer subtypes: a pooled analysis of case-control studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.10.001

Obesity and risk of ovarian cancer subtypes: evidence from the Ovarian Cancer Association Consortium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.10.001

Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case-control studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.10.001

Ovarian cancer and smoking: individual participant meta-analysis including 28,114 women with ovarian cancer from 51 epidemiological studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.10.001

Combined oral contraceptive use before the first birth and epithelial ovarian cancer risk

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.10.001

Ovarian Cancer Risk Factors by Histologic Subtype: An Analysis From the Ovarian Cancer Cohort Consortium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.10.001

Environmental and heritable factors in the causation of cancer--analyses of cohorts of twins from Sweden, Denmark, and Finland

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.10.001

A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.10.001

Identification of the breast cancer susceptibility gene BRCA2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.10.001

Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.10.001

Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.10.001

Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.10.001

Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.10.001

The contribution of germline BRCA1 and BRCA2 mutations to familial ovarian cancer: no evidence for other ovarian cancer-susceptibility genes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.10.001

BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.10.001

Germline mutations of the BRCA1 gene in breast and ovarian cancer families provide evidence for a genotype–phenotype correlation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.10.001

Variation of risks of breast and ovarian cancer associated with different germline mutations of the BRCA2 gene

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.10.001

Variation in cancer risks, by mutation position, in BRCA2 mutation carriers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.10.001

Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.10.001

Mouse models of BRCA1 and their application to breast cancer research

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.10.001

Mouse models of BRCA1 and BRCA2 deficiency: past lessons, current understanding and future prospects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.10.001

Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.10.001

Identification of six new susceptibility loci for invasive epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.10.001

The contribution of deleterious germline mutations in BRCA1, BRCA2 and the mismatch repair genes to ovarian cancer in the population

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.10.001

Contribution ofBRCA1andBRCA2mutations to inherited ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.10.001

BRCA1 and BRCA2 mutation prevalence and clinical characteristics of a population-based series of ovarian cancer cases from Denmark.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.10.001

Role of BRCA1 and BRCA2 as regulators of DNA repair, transcription, and cell cycle in response to DNA damage

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.10.001

Genome maintenance mechanisms for preventing cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.10.001

Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.10.001

Germline mutations in RAD51D confer susceptibility to ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.10.001

Germline RAD51C mutations confer susceptibility to ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.10.001

Mutations in BRIP1 confer high risk of ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.10.001

Germline Mutations in the BRIP1, BARD1, PALB2, and NBN Genes in Women With Ovarian Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.10.001

Contribution of Germline Mutations in the RAD51B, RAD51C, and RAD51D Genes to Ovarian Cancer in the Population

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.10.001

Inherited Mutations in Women With Ovarian Carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.10.001

Germline whole exome sequencing and large-scale replication identifies FANCM as a likely high grade serous ovarian cancer susceptibility gene

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.10.001

The contribution of DNA mismatch repair gene defects to the burden of gynecological cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.10.001

Ovarian cancer linked to Lynch syndrome typically presents as early-onset, non-serous epithelial tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.10.001

Frequency of mutations in mismatch repair genes in a population-based study of women with ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.10.001

Hereditary predisposition to ovarian cancer, looking beyond BRCA1/BRCA2.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.10.001

Cancer risk in MLH1, MSH2 and MSH6 mutation carriers; different risk profiles may influence clinical management

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.10.001

Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.10.001

A genome-wide association study identifies a new ovarian cancer susceptibility locus on 9p22.2.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.10.001

A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.10.001

Common variants at 19p13 are associated with susceptibility to ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.10.001

GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.10.001

Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.10.001

Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.10.001

Identification and molecular characterization of a new ovarian cancer susceptibility locus at 17q21.31.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.10.001

Genome-wide association study identifies new susceptibility loci for epithelial ovarian cancer in Han Chinese women.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.10.001

Genome-wide significant risk associations for mucinous ovarian carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.10.001

Genome-Wide Meta-Analyses of Breast, Ovarian, and Prostate Cancer Association Studies Identify Multiple New Susceptibility Loci Shared by at Least Two Cancer Types

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.10.001

Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.10.001

Multiple loci with different cancer specificities within the 8q24 gene desert

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.10.001

HNF1B variants associate with promoter methylation and regulate gene networks activated in prostate and ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.10.001

Cis-eQTL analysis and functional validation of candidate susceptibility genes for high-grade serous ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.10.001

Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.10.001

Assessing the genetic architecture of epithelial ovarian cancer histological subtypes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.10.001

Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.10.001

Long-term ovarian cancer survival associated with mutation in BRCA1 or BRCA2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.10.001

Clinical characteristics of ovarian cancer classified by BRCA1, BRCA2, and RAD51C status

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.10.001

Germline mutation in BRCA1 or BRCA2 and ten-year survival for women diagnosed with epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.10.001

Mismatch repair gene polymorphisms and survival in invasive ovarian cancer patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.10.001

The Effects of Common Genetic Variants in Oncogenes on Ovarian Cancer Survival

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.10.001

Effects of common germ-line genetic variation in cell cycle genes on ovarian cancer survival

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.10.001

Functional complementation studies identify candidate genes and common genetic variants associated with ovarian cancer survival

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.10.001

Genome-wide Analysis Identifies Novel Loci Associated with Ovarian Cancer Outcomes: Findings from the Ovarian Cancer Association Consortium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.10.001

New treatment option for ovarian cancer: PARP inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.10.001

Update on Poly-ADP-ribose polymerase inhibition for ovarian cancer treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.10.001

A final report of a phase I study of veliparib (ABT-888) in combination with low-dose fractionated whole abdominal radiation therapy (LDFWAR) in patients with advanced solid malignancies and peritoneal carcinomatosis with a dose escalation in ovaria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.10.001

Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.10.001

Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.10.001

Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.10.001

PARP inhibitors for BRCA1/2-mutated and sporadic ovarian cancer: current practice and future directions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.10.001

Implementing rapid, robust, cost-effective, patient-centred, routine genetic testing in ovarian cancer patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.10.001

BRCA1 and BRCA2 mutations in women of different ethnicities undergoing testing for hereditary breast-ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.10.001

NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2017.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.10.001

Counselling framework for moderate-penetrance cancer-susceptibility mutations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.10.001

Analysis of protein-coding genetic variation in 60,706 humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.10.001

BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.10.001

Large-scale genotyping identifies 41 new loci associated with breast cancer risk

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.10.001

A meta-analysis of estrogen replacement therapy and risk of epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.10.001

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.YGYNO.2017.10.001

1 reference

24 February 2018

1 reference

24 February 2018